Dainippon Sumitomo To Expand U.S., Canada Sales Force By 30%
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma said it plans to expand its U.S. and Canada staff of medical representatives for antipsychotic drugs by nearly a third to market its Latuda (lurasidone) schizophrenia treatment.